Atea Pharmaceuticals Stock Financials

AVIR -  USA Stock  

USD 24.74  0.37  1.47%

Understanding current and past Atea Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Atea Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Atea Pharmaceuticals' assets may result in an increase in income on the income statement. Because of this, it is necessary to analyze all of Atea Pharmaceuticals' financials over time to get the whole picture. As of 07/26/2021, Net Income Per Employee is likely to drop to about (345.7 K). In addition to that, Revenue Per Employee is likely to drop to about 1 M.
Use fundamental data analysis to double-check all available reported financial drivers of Atea Pharmaceuticals to find out if markets are presently mispricing the company. We were able to collect and analyze data for thirty-three available fundamental indicators for Atea Pharmaceuticals, which can be compared to its rivals. To make sure the equity is not overpriced, please confirm all Atea Pharmaceuticals financials, including its cash and equivalents, total asset, and the relationship between the price to sales and short ratio . Given that Atea Pharmaceuticals has a number of shares shorted of 4.25 M, we suggest you to validate Atea Pharmaceuticals prevailing market performance to make sure the company can sustain itself down the road. Use Atea Pharmaceuticals to protect your portfolios against small market fluctuations. The stock experiences a somewhat bearish sentiment, but the market may correct it shortly. Check odds of Atea Pharmaceuticals to be traded at $24.0 in 90 days.

Search Fundamentals 

 
Refresh
With this module, you can analyze Atea Pharmaceuticals financials for your investing period. You should be able to track the changes in Atea Pharmaceuticals individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
  Chance Of Financial Distress
Over 72
Atea Pharmaceuticals has more than 72 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Atea Pharmaceuticals stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Atea Pharmaceuticals' official financial statements usually reflect Atea Pharmaceuticals' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Atea Pharmaceuticals. For example, before you start analyzing numbers published by Atea Pharmaceuticals accountants, it's critical to develop an understanding of what Atea Pharmaceuticals' liquidity, profitability, and earnings quality are in the context of the Pharmaceutical Products space in which it operates.
Please note, the presentation of Atea Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atea Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Atea Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Atea Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Atea Pharmaceuticals' management to manipulate its earnings.

Atea Pharmaceuticals Company Summary

Atea Pharmaceuticals competes with Equillium, Diamedica Therapeutics, Denali Therapeutics, Dicerna Pharmaceutic, and Design Therapeutics. Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts. Atea Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs people.
Specialization
Healthcare, Biotechnology
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0000072444
CUSIP04683R106
RegionNorth America
LocationMassachusetts; U.S.A
Business Address2500 Northwinds Parkway
BenchmarkDOW
Websitewww.aviragentherapeutics.com
Phone678 221 3343
CurrencyUSD - US Dollar

Atea Pharmaceuticals Key Financial Ratios

Generally speaking, Atea Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Atea Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Atea Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Atea Pharmaceuticals reports annually and quarterly.

Atea Pharmaceuticals Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Atea Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Atea Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Atea Pharmaceuticals competition to find correlations between indicators driving Atea Pharmaceuticals's intrinsic value. More Info.
Atea Pharmaceuticals is number one stock in book value per share category among related companies. It is rated third in cash flow from operations category among related companies making about  22,668,449  of Cash Flow from Operations per Book Value Per Share. . Atea Pharmaceuticals Book Value per Share is relatively stable at the moment as compared to the past year. Atea Pharmaceuticals reported last year Book Value per Share of 25.37

Atea Pharmaceuticals Systematic Risk

Atea Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Atea Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Atea Pharmaceuticals correlated with the market. If Beta is less than 0 Atea Pharmaceuticals generally moves in the opposite direction as compared to the market. If Atea Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Atea Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Atea Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Atea Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About Atea Pharmaceuticals Financials

What exactly are Atea Pharmaceuticals Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Atea Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows. Potential Atea Pharmaceuticals investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Atea Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Atea Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Atea Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2015 2016 2020 2021 (projected)
Accounts Payable3.9 M1.4 M131.4 K134.86 K
Receivables700 K600 K895.5 K919.07 K

Atea Pharmaceuticals July 26, 2021 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Atea Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Atea Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Atea Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Atea Pharmaceuticals Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Atea Pharmaceuticals's daily price indicators and compare them against related drivers.
Information Ratio(0.10)
Maximum Drawdown31.2
Value At Risk(8.27)
Potential Upside8.73
Please continue to Trending Equities. Note that the Atea Pharmaceuticals information on this page should be used as a complementary analysis to other Atea Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Complementary Tools for Atea Pharmaceuticals Stock analysis

When running Atea Pharmaceuticals price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Piotroski F Score
Get Piotroski F Score based on binary analysis strategy of nine different fundamentals
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
The market value of Atea Pharmaceuticals is measured differently than its book value, which is the value of Atea Pharmaceuticals that is recorded on the company's balance sheet. Investors also form their own opinion of Atea Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Atea Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Atea Pharmaceuticals' market value can be influenced by many factors that don't directly affect Atea Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Atea Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Atea Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Atea Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.